paclitaxel and byl719
paclitaxel has been researched along with byl719 in 4 studies
Research
Studies (4)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 4 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
Hou, Y; Kuang, W; Min, W; Sun, C; Wang, L; Wang, X; Wang, Y; Xia, F; Yang, P; Yuan, K; Zhang, F; Zhang, H; Zhu, Y | 1 |
Abramson, VG; Ayers, GD; Chen, SC; Mayer, IA; Richmond, A; Saleh, N; Yan, C; Yang, J | 1 |
Other Studies
4 other study(ies) available for paclitaxel and byl719
Article | Year |
---|---|
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer.
Topics: Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Humans; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Phosphoinositide-3 Kinase Inhibitors; Stomach Neoplasms; Structure-Activity Relationship | 2022 |
Continuing Advancements in Breast Cancer Care.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Humans; Medical Oncology; Paclitaxel; Thiazoles | 2021 |
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Granulocytes; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |